Literature DB >> 28869177

Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer.

M Mayoral1, P Paredes2, A Saco3, P Fusté4, P Perlaza1, A Tapias1, A Fernandez-Martinez5, L Vidal5, J Ordi6, J Pavia7, S Martinez-Roman8, F Lomeña9.   

Abstract

OBJECTIVE: Standardised uptake value (SUV) and volumetric parameters such as metabolic tumour volume (MTV) and total lesion glycolysis (TLG) from 18F-FDG PET/CT are useful criteria for disease prognosis in pre-operative and post-treatment epithelial ovarian cancer (EOC). Ki67 is another prognostic biomarker in EOC, associated with tumour aggressiveness. The aim of this study is to evaluate the association between 18F-FDG PET/CT measurements and Ki67 in pre-treatment EOC to determine if PET/CT parameters could non-invasively predict tumour aggressiveness.
MATERIAL AND METHODS: A pre-treatment PET/CT was performed on 18 patients with suspected or newly diagnosed EOC. Maximum SUV (SUVmax), mean SUV (SUVmean), whole-body MTV (wbMTV), and whole-body TLG (wbTLG) with a threshold of 30% and 40% of the SUVmax were obtained. Furthermore, Ki67 index (mean and hotspot) was estimated in tumour tissue specimens. Immunohistochemical findings were correlated with PET parameters.
RESULTS: The mean age was 57.0 years old (standard deviation 13.6 years). A moderate correlation was observed between mean Ki67 index and SUVmax (r=0.392), SUVmean 30% (r=0.437), and SUVmean 40% (r=0.443), and also between hotspot Ki67 index and SUVmax (r=0.360), SUVmean 30% (r=0.362) and SUVmean 40% (r=0.319). There was a weaker correlation, which was inversely negative, between mean and hotspot Ki67 and volumetric PET parameters. However, no statistical significant differences were found for any correlations.
CONCLUSIONS: SUVmax and SUVmean were moderately correlated with Ki67 index, whereas volumetric PET parameters overall, showed a weaker correlation. Thus, SUVmax and SUVmean could be used to assess tumour aggressiveness in pre-treatment EOC.
Copyright © 2017 Elsevier España, S.L.U. y SEMNIM. All rights reserved.

Entities:  

Keywords:  (18)F-FDG PET/CT; (18)F-FDG PET/TC; Cáncer epitelial de ovario; Epithelial ovarian cancer; Ki67; Metabolic tumour volume; SUV; Total lesion glycolysis

Mesh:

Substances:

Year:  2017        PMID: 28869177     DOI: 10.1016/j.remn.2017.07.005

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol (Engl Ed)        ISSN: 2253-8089


  4 in total

1.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

2.  Role of dual-time point 18F-FDG PET/CT imaging in the primary diagnosis and staging of hilar cholangiocarcinoma.

Authors:  Lifang Pang; Xiaobo Bo; Jie Wang; Changcheng Wang; Yueqi Wang; Guobing Liu; Haojun Yu; Lingli Chen; Hongcheng Shi; Houbao Liu
Journal:  Abdom Radiol (NY)       Date:  2021-04-07

3.  Outcomes of surgical resection for pulmonary metastasis from ovarian cancer.

Authors:  Ryu Kanzaki; Jiro Okami; Koji Takami; Teruo Iwasaki; Naoki Ikeda; Yasunobu Funakoshi; Yasushi Sakamaki; Ken Kodama; Hideoki Yokouchi; Yoshihisa Kadota; Naoko Ose; Yasushi Shintani
Journal:  J Cardiothorac Surg       Date:  2020-07-23       Impact factor: 1.637

4.  Habitat radiomics analysis of pet/ct imaging in high-grade serous ovarian cancer: Application to Ki-67 status and progression-free survival.

Authors:  Xinghao Wang; Chen Xu; Marcin Grzegorzek; Hongzan Sun
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.